Financial Data and Key Metrics Changes - Cardinal Health reported total revenue for Q2 2026 increased by 19% to $66 billion, driven by strong demand in the pharmaceutical and specialty solutions segment [9][12] - Gross margin dollars increased by 24% to $2.4 billion, reflecting a favorable mix across businesses [9] - Operating earnings rose by 38% to $877 million compared to the prior year [10] - Non-GAAP diluted EPS for the quarter was $2.63, a 36% increase from $1.93 in the same quarter last year [11] Business Line Data and Key Metrics Changes - Pharmaceutical and Specialty Solutions segment revenue increased by 19% to $61 billion, with segment profit rising by 29% to $687 million [12] - GMPD segment revenue grew by 3% to $3.3 billion, with segment profit increasing to $37 million from $18 million in the prior year [13] - Other growth businesses, including Nuclear and Precision Health Solutions, At-Home Solutions, and OptiFreight Logistics, saw revenue increase by 34% to $1.7 billion, with segment profit up by 52% to $179 million [14][15] Market Data and Key Metrics Changes - The company expects specialty revenues to surpass $50 billion in fiscal 2026, indicating strong growth in this high-margin area [5] - The GMPD segment's revenue growth was partially driven by inventory restocking by distributors, which is expected to normalize in Q3 [13][20] Company Strategy and Development Direction - Cardinal Health is focused on strengthening its core business while expanding in specialty and other growth areas, with a commitment to operational excellence and simplification [4][23] - The acquisition of Solaris Health is expected to enhance the company's specialty platform and expand its capabilities [5][25] - The company is raising its fiscal year 2026 earnings per share guidance to a range of $10.15-$10.35, reflecting confidence in continued performance [18][19] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the resilience of the business model and the ability to navigate the dynamic healthcare environment [23][31] - The company anticipates mid-teens profit growth in the second half of the fiscal year, despite not assuming outsized demand [19][38] - Management highlighted the importance of maintaining strong relationships with customers and adapting to market changes [91] Other Important Information - Cardinal Health generated $1.8 billion in adjusted free cash flow year-to-date and ended the quarter with a cash position of $2.8 billion [17] - The company has returned $1 billion to shareholders so far this year, including $750 million through share repurchase programs [17] Q&A Session Summary Question: Can you unpack or break down some of the components of the profit performance in Pharma Solutions? - Management noted strong demand across all categories in the pharma business, with significant contributions from specialty and generics, and emphasized strong execution by operations teams [34][35] Question: Is ADS performing ahead of your expectations? - Management indicated that the ADS acquisition is performing consistently with expectations, and core business remains strong across all three businesses in the other segment [43][44] Question: Can you provide more on capital allocation and opportunities for further transactions? - Management emphasized a disciplined capital allocation framework and noted flexibility to assess growth opportunities while protecting the core business [50][51] Question: How do you see the macro pricing environment impacting your guidance? - Management stated that anticipated changes in manufacturer pricing would be adjusted within the cost structure to preserve margins, with no significant impact expected on revenue [75][76] Question: How is the company modeling revenue or earnings for GLP-1s this year? - Management indicated that while GLP-1s have seen significant volume growth, they do not expect it to be a major driver of underlying profitability moving forward [81][82]